



27 March 2018

Dr Bradley Wilsmore
Cardiology Department
John Hunter Hospital

Dear Dr Wilsmore

Re: NP202 in paroxysmal AF: A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults with paroxysmal atrial fibrillation and a cardiac device (17/11/15/3.01)

HNEHREC Reference No: 17/11/15/3.01
NSW HREC Reference No: HREC/17/HNE/503
SSA Reference No: SSA/18/HNE/83

Thank you for submitting an application for authorisation of this project. I am pleased to inform you that authorisation has been granted for this study to take place at the following sites:

- **John Hunter Hospital**

The following conditions apply to this research project. These are additional to those conditions imposed by the Human Research Ethics Committee that granted ethical approval:

1. Proposed amendments to the research protocol or conduct of the research which may affect the ethical acceptability of the project, and which are submitted to the lead HREC for review, are copied to the research governance officer;
2. Proposed amendments to the research protocol or conduct of the research which may affect the ongoing site acceptability of the project, are to be submitted to the research governance officer;
3. Annual Report submitted to the lead HREC for review and the acknowledgment, are copied to the research governance officer;
4. Final Report submitted to the lead HREC for review and the acknowledgement, are copied to the research governance officer.

Yours faithfully

Dr Nicole Gerrand
Research Governance Officer
Hunter New England Local Health District

Hunter New England Research Ethics & Governance Office

Locked Bag No 1

New Lambton NSW 2305

Telephone: (02) 49214950

Email: HNELHD-HREC@hnehealth.nsw.gov.au

<http://www.hnehealth.nsw.gov.au/ethics/Pages/Research-Ethics-and-Governance-Unit.aspx>